Molecular studies of liver disease in erythropoietic protoporphyria

Journal of Clinical Gastroenterology

Volumn 39, Issue 4 SUPPL., 2005, Pages

  Bloomer, Joseph ^a   Wang, Yongming ^a   Singhal, Anuj ^a   Risheg, Hiba ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

DNA microarray; Erythropoietic protoporphyria; Ferrochelatase

Indexed keywords

FERROCHELATASE; PROTOPORPHYRIN;

ADOLESCENT; ADULT; ANION TRANSPORT; ARTICLE; BILE FLOW; DNA MICROARRAY; DNA POLYMORPHISM; ERYTHROPOIETIC PROTOPORPHYRIA; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; WOUND HEALING;

EID: 15444378400     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000155518.96629.ea     Document Type: Article

References (55)

1. Bonkowsky HL, Bloomer JR, Ebert PS, et al. Heme synthetase deficiency in human protoporphyria: demonstration of the defect in liver and cultured skin fibroblasts. J Clin Invest. 1975;56:1139-1148.
2. Bottomley SS, Tanaka M, Everett MA. Diminished erythroid ferrochelatase activity in protoporphyria. J Lab Clin Med. 1975;86:126-131.
3. Taketani S, Inazawa J, Nakahashi Y, et al. Structure of human ferrochelatase gene: exon/intron gene organization and location of the gene to chromosome 18. Eur J Biochem. 1992;205:217-222.
4. Tugores A, Magness ST, Brenner DA. A single promoter directs both housekeeping and erythroid preferential expression of the human ferrochelatase gene. J Biol Chem. 1994;269:30789-30797.
5. Nakahashi Y, Taketani S, Okuda M, et al. Molecular cloning and sequence analysis of cDNA encoding human ferrochelatase. Biochem Biophys Res Commun. 1990;173:748-755.
6. Wu CK, Dailey HA, Rose JP, et al. The 2A structure of human ferrochelatase, the terminal enzyme of heme biosynthesis. Nat Struct Biol. 2000;8:145-160.
7. Straka JG, Bloomer JR, Kempner ES. The functional size of ferrochelatase determined in situ by radiation inactivation. J Biol Chem. 1991;266:24637-24641.
8. Rufenacht UB, Gouya L. Schneider-Yin X, et al. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet. 1998;62:1341-1352.
9. Bloomer JR, Poh-Fitzpatrick MB. Pathogenesis of biochemical abnormalities in protoporphyria. Trans Am Clin Climatol Assoc. 2000;111:245-257.
10. Sarkany RP. Erythropoietic protoporphyria (EPP) at 40. Where are we now? Photodermatol Photoimmunol Photomed. 2002;18:147-152.
11. Poh-Fitzpatrick MB. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatology. 1986;3:148-157.
12. Bloomer JR, Phillips MJ, Davidson DL, et al. Hepatic disease in erythropoietic protoporphyria. Am J Med. 1975;58:869-882.
13. Doss MO, Frank M. Hepatobiliary implications and complications in protoporphyria: a 20 year study. Clin Biochem. 1989;22:223-229.
14. Avner DL, Lee RG, Berenson MM. Protoporphyrin-induced cholestasis in the isolated in situ perfused rat liver. J Clin Invest. 1981;67:385-394.
15. Meerman LL, Koopen NR, Bloks V, et al. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology. 1999;117:696-705.
16. Bloomer JR, Rank JM, Payne WD, et al. Follow-up after liver transplantation for protoporphyric liver disease. Liver Transpl Surg. 1996;2:269-275.
17. Gouya L, Puy H, Robreau AB, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet. 2002;30:27-28.
18. Wiman A, Floderus Y, Harper P. Novel mutations and phenotypic effect of the splice site modulator IVS3-48c in nine Swedish families with EPP. J Hum Genet. 2003;48:70-76.
19. Risheg H, Chen FP, Bloomer JR. Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyria. Mol Genet Metab. 2003;80:196-206.
20. Morton KD, Schneider F, Weimer MK, et al. Hepatic and bile porphyrins in patients with protoporphyria and liver failure. Gastroenterology. 1988; 94:1488-1492.
21. Chen FP, Risheg H, Liu Y, et al. Ferrochelatase gene mutations in erythropoietic protoporphyria: focus on liver disease. Cell Mol Biol. 2002; 48:83-89.
22. Sellers VM, Dailey TA, Dailey HA. Examination of ferrochelatase mutations that cause erythropoietic protoporphyria. Blood. 1998;91:3980-3985.
23. Whiting MJ, Granick S. Aminolevulinic acid synthase from chick embryo liver mitochondria: II. Immunochemical correlation between synthesis and activity in induction and repression. J Biol Chem. 1976;251:1347-1353.
24. Bissell DM, Hammaker LE. Cytochrome P-450 heme and the regulation of aminolevulinic acid synthetase in the liver. Arch Biochem Biophys. 1976;176:103-112.
25. Litman DA, Correia MA. L-tryptophan: a common denominator of biochemical and neurological events of acute hepatic porphyria. Science. 1983;222:1031-1033.
26. Knobler E, Poh-Fitzpatrick MB, Kravetz D, et al. Interaction of hemopexin, albumin and liver fatty acid-binding protein with protoporphyrin. Hepatology. 1989;10:995-997.
27. Beu Keveld GJJJ, In't Veld G, Havinga R, et al. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J Hepatol. 1996;24: 343-352.
28. Piösch T, Bloks VW, Baller JFW, et al. Mdr P-glycoproteins are not essential for biliary excretion of the hydrophobic heme precursor protoporphyrin in a griseofulvin-induced mouse model of erythropoietic protoporphyria. Hepatology. 2002;35:299-306.
29. Jansen PLM, Müller M, Sturm E. Genes and cholestasis. Hepatology. 2001;34:1067-1074.
30. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83:633-671.
31. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology. 2004;126:322-342.
32. Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33:633-646.
33. Soroka CJ, Lee JM, Azzaroli F, et al. Cellular localization and upregulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology. 2001;33:783-791.
34. Vile GF, Basu-Modak S, Waltner C, et al. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci USA. 1994;91:2607-2610.
35. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA. 1997;94:10925-10930.
36. Scholnick P, Marver HS, Schmid R. Erythropoietic protoporphyria: evidence for multiple sites of excess protoporphyrin formation. J Clin Invest. 1971;50:203-207.
37. Lamon JM, Poh-Fitzpatrick MB, Lamola AA, et al. Hepatic protoporphyrin production in human protoporphyria: effects of intravenous hematin and analysis of erythrocyte protoporphyrin distribution. Gastroenterology. 1980;79:115-125.
38. Poh-Fitzpatrick MB. Protoporphyrin metabolic balance in human protoporphyria. Gastroenterology. 1985;88:1239-1242.
39. Bloomer J, Bruzzone C, Zhu L, et al. Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation. J Clin Invest. 1998;102:107-114.
40. Wolfson SJ, Bartczak A, Bloomer JR. Effect of endogenous heme generation on aminolevulinic acid synthase activity in rat liver mitochondria. J Biol Chem. 1979;254:3543-3546.
41. Tutois S, Montagutelli X, DaSilva V, et al. Erythropoietic protoporphyria in the house mouse: a recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease. J Clin Invest. 1991;88:1730-1736.
42. Avner DL, Berenson MM. Hepatic clearance and biliary secretion of protoporphyrin in the isolated, in situ perfused rat liver. J Lab Clin Med. 1982;99:885-894.
43. Avner DL, Larsen R, Berenson MM. Inhibition of liver surface membrane, Na, K-adenosine triphosphatase, Mg-adenosine triphosphatase and 5′-nucleotidase activities by protoporphyrin: observations in vitro and in the perfused rat liver. Gastroenterology. 1983;85:700-706.
44. Bloomer JR, Enriquez R. Evidence that hepatic crystalline deposits in a patient with protoporphyria are composed of protoporphyrin. Gastroenterology. 1982;82:569-572.
45. Berenson MM, El-Mir MY, Zhang L-K. Mechanism of bile acid facilitation of biliary protoporphyrin excretion in rat liver. Am J Physiol. 1995;268:G754-G763.
46. Libbrecht L, Meerman L, Kuipers F, et al. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol. 2003;199:191-200.
47. Rademakers LHPM, Cleten MI, Kooijman C, et al. Early involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural study of patients with and without overt liver disease and the effect of chemodeoxycholic acid treatment. Hepatology. 1990;11:449-457.
48. Koningsberger JC, Van Asbeck BS, Van Hattum J, et al. The effect of porphyrins on cellular redox systems: a study on the dark effect of porphyrins on phagocytes. Eur J Clin Invest. 1993;23:716-723.
49. Koningsberger JC, Rademakers LHPM, Van Hattum J, et al. Exogenous protoporphyrin inhibits Hep G2 cell proliferation, increases the intracellular hydrogen peroxide concentration and causes ultrastructural alterations. J Hepatol. 1995;22:57-65.
50. Robertson G, Leclereq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis: II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1135-G1139.
51. McGuire BM, Bonkovsky HL, Carithers RL, et al. Liver transplantation for erythropoietic protoporphyria. Hepatology. 2004;40:551A.
52. Pawliuk R, Bachelot T, Wise RJ, et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med. 1999;5:768-773.
53. Fontanellas A, Mazurier F, Landry M, et al. Reversion of hepatobiliary alterations by bone marrow transplantation in a mouse model of erythropoietic protoporphyria. Hepatology. 2000;32:73-81.
54. Fontanellas A, Mendez M, Mazurier F, et al. Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Gene Ther. 2001;8:618-626.
55. Poh-Fitzpatrick MB, Wang X, Anderson KE, et al. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol. 2002;46:861-866.